Zimmer Biomet (NYSE:ZBH) Rating Lowered to “Hold” at Wall Street Zen

Zimmer Biomet (NYSE:ZBH) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

Several other brokerages also recently issued reports on ZBH. JPMorgan Chase & Co. reissued a “neutral” rating and set a $100.00 price target (down previously from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Redburn Partners set a $130.00 target price on shares of Zimmer Biomet in a research note on Thursday, September 18th. UBS Group dropped their price target on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research note on Thursday, November 6th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Thursday, August 7th. Finally, BTIG Research lowered their target price on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $109.00.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $89.86 on Friday. The company has a market cap of $17.81 billion, a P/E ratio of 21.86, a PEG ratio of 2.29 and a beta of 0.67. The business has a 50 day moving average of $98.56 and a two-hundred day moving average of $97.07. Zimmer Biomet has a 52 week low of $85.33 and a 52 week high of $114.72. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The business had revenue of $2 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same period in the prior year, the firm earned $1.74 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current year.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. raised its holdings in shares of Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after acquiring an additional 3,208,596 shares during the period. Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 12.9% in the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares in the last quarter. Norges Bank purchased a new stake in shares of Zimmer Biomet in the second quarter valued at $225,867,000. JPMorgan Chase & Co. boosted its position in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after buying an additional 1,488,918 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Zimmer Biomet during the first quarter valued at $155,891,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.